Update on Clinical Strategies in Hereditary Hemorrhagic Telangiectasia from an ENT Point of View
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives. Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of vascular malformations with an absence of capillaries between arteries and veins. One major manifestation site is the nasal mucous membrane where recurrent nosebleeds occur. Our clinical strategy to treat patients with HHT has the aim to reduce nasal bleeding long-term with minimal local and general side effects. Methods. We describe staged diagnosis and therapy including individual medical treatments of 97 patients with HHT. The success of treatment is monitored with a systematic questionnaire. Results. The neodymium-doped yttrium aluminium garnet (Nd:YAG) laser therapy remains standard treatment of choice with no major side effects despite the need for repeated treatment. In addition new treatment strategies like nasal occlusion, local drug therapy, and nasal septal splinting show initial success. Conclusion. Improvement of the quality of life of HHT patients can be achieved by a multimodal concept. Several new treatment strategies like nasal septal splinting and nasal occlusion successfully expand the range of established methods. Further studies have to prove the safety and long-term effectiveness of the described individual medical treatments.
Abstract
Objectives. Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of vascular malformations with an absence of capillaries between arteries and veins. One major manifestation site is the nasal mucous membrane where recurrent nosebleeds occur. Our clinical strategy to treat patients with HHT has the aim to reduce nasal bleeding long-term with minimal local and general side effects. Methods. We describe staged diagnosis and therapy including individual medical treatments of 97 patients with HHT. The success of treatment is monitored with a systematic questionnaire. Results. The neodymium-doped yttrium aluminium garnet (Nd:YAG) laser therapy remains standard treatment of choice with no major side effects despite the need for repeated treatment. In addition new treatment strategies like nasal occlusion, local drug therapy, and nasal septal splinting show initial success. Conclusion. Improvement of the quality of life of HHT patients can be achieved by a multimodal concept. Several new treatment strategies like nasal septal splinting and nasal occlusion successfully expand the range of established methods. Further studies have to prove the safety and long-term effectiveness of the described individual medical treatments.
참고문헌 (22)
- Braverman IM, "Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia", J Invest Dermatol., 95(4), pp.422~427 (1990)
- Faughnan ME, "International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia", J Med Genet, 48(2), pp.73~87 (2011)
- Byahatti SV, "Hereditary hemorrhagic telangiectasia: what the otolaryngologist should know", Am J Rhinol, 11(1), pp.55~62 (1997)
- Geisthoff UW, "Hereditary hemorrhagic telangiectasia (Osler’s disease): an interdisciplinary challenge", HNO, 50(2), pp.114~128 (2002)
- Guttmacher AE, "Hereditary hemorrhagic telangiectasia", N Engl J Med, 333(14), pp.918~924 (1995)
- Porteous ME, "Hereditary haemorrhagic telangiectasia: a clinical analysis", J Med Genet, 29(8), pp.527~530 (1992)
- van Gent MW, "Hereditary hemorrhagic telangiectasia : how accurate are the clinical criteria?", Am J Med Genet A, 161(3), pp.461~466 (2013)
- Kuhnel TS, "Clinical strategy in hereditary hemorrhagic telangiectasia", Am J Rhinol, 19(5), pp.508~513 (2005)
- Rohrmeier C, "A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia", Eur Arch Otorhinolaryngol, 269(2), pp.531~536 (2012)
- Golding-Wood PH., "The role of arterial ligation in intractable epistaxis", J Laryngol Otol, 8, pp.120~122 (1983)
- Werner JA, "Treatment of recurrent epistaxis in Rendu-Osler-Weber disease", HNO, 45(9), pp.673~681 (1997)
- Parkin JL, "Laser photocoagulation in hereditary hemorrhagic telangiectasia", Otolaryngol Head Neck Surg, 89(2), pp.204~208 (1981)
- Shapshay SM, "Treatment of hereditary hemorrhagic telangiectasia by Nd-YAG laser photocoagulation", Laryngoscope, 94(12 Pt 1), pp.1554~1556 (1984)
- Kluger PB, "Neodymium-YAG laser intranasal photocoagulation in hereditary hemorrhagic telangiectasia: an update report", Laryngoscope, 97(12), pp.1397~1401 (1987)
- Folz BJ, "Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease", Rhinology, 43(1), pp.40~46 (2005)
- Mahoney EJ, "New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia", Am J Rhinol, 20(1), pp.87~90 (2006)
- Gluckman JL, "Modified Young’s procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia", Laryngoscope, 104(9), pp.1174~1177 (1994)
- Al Kadah B, "First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT)", Eur Arch Otorhinolaryngol, 272(1), pp.117~122 (2015)
- Sadick H, "Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression", Haematologica, 90(6), pp.818~828 (2005)
- Fischer M, "Critical evaluation of vascular embolization in patients with Rendu-Osler disease", Laryngorhinootologie, 76(8), pp.490~494 (1997)
- Elden L, "Angiographic embolization for the treatment of epistaxis: a review of 108 cases", Otolaryngol Head Neck Surg, 111(1), pp.44~50 (1994)
- Dubel GJ, "Transcatheter embolization in the management of epistax", Semin Intervent Radiol, 30(3), pp.249~262 (2013)